OPKO Health, Inc. (NASDAQ:OPK) CEO Acquires $740,000.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 500,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were acquired at an average cost of $1.48 per share, with a total value of $740,000.00. Following the transaction, the chief executive officer now owns 213,036,477 shares in the company, valued at approximately $315,293,985.96. This represents a 0.24 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, December 13th, Phillip Md Et Al Frost acquired 125,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.59 per share, with a total value of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.56 per share, for a total transaction of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost purchased 199,072 shares of OPKO Health stock. The stock was bought at an average price of $1.53 per share, with a total value of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.59 per share, for a total transaction of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was bought at an average price of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost purchased 280,183 shares of OPKO Health stock. The shares were bought at an average cost of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Price Performance

OPK stock opened at $1.47 on Thursday. The stock’s 50 day moving average is $1.54 and its two-hundred day moving average is $1.50. OPKO Health, Inc. has a 52-week low of $0.86 and a 52-week high of $1.76. The company has a market capitalization of $1.00 billion, a PE ratio of -7.74 and a beta of 1.62. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

Analysts Set New Price Targets

Several analysts have issued reports on OPK shares. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, January 8th. StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Barrington Research reiterated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th.

Institutional Trading of OPKO Health

A number of hedge funds have recently made changes to their positions in the stock. Rubric Capital Management LP raised its holdings in OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after acquiring an additional 4,284,336 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of OPKO Health by 142.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock worth $2,227,000 after purchasing an additional 876,272 shares during the last quarter. PFG Investments LLC raised its stake in shares of OPKO Health by 10.4% in the 3rd quarter. PFG Investments LLC now owns 1,061,090 shares of the biotechnology company’s stock valued at $1,581,000 after purchasing an additional 100,125 shares in the last quarter. Clearline Capital LP bought a new position in shares of OPKO Health during the third quarter worth about $1,083,000. Finally, Barclays PLC grew its stake in OPKO Health by 154.5% in the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after purchasing an additional 329,870 shares in the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.